Santhera Pharmaceutical Holding Ltd

Company

Santhera is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule products for the treatment of severe neuromuscular diseases, an area of high unmet medical needs.

Clinical Trials

Santhera is currently recruiting patients for clinical studies in
  • Friedreich’s Ataxia in US and Europe
  • Leber’s Hereditary Optic Neuropathy in Germany and in UK
  • Dyskinesia in Parkinson’s Disease in US

Development Programs

Santhera has three compounds in five clinical programs: SNT-MC17 in Friedreich’s Ataxia, Duchenne Muscular Dystrophy and Leber’s Hereditary Optic Neuropathy, JP-1730 in Dyskinesia in Parkinson’s, and SNT-317 in Congenital Muscular Dystrophy.
See the full pipeline

Latest News

April 21, 2008
Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
---
April 11, 2008
Santhera Presents Efficacy Data of SNT-MC17 in DMD at AAN Annual Meeting
---
February 29, 2008
Santhera Reports Financial Results and Significant Operational Progress for 2007